Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02844439
Recruitment Status : Completed
First Posted : July 26, 2016
Results First Posted : September 22, 2021
Last Update Posted : September 22, 2021
Sponsor:
Information provided by (Responsible Party):
Kadmon Corporation, LLC

Brief Summary:
This is a multicenter, Phase 2 study to assess the activity of tesevatinib in patients with recurrent glioblastoma.

Condition or disease Intervention/treatment Phase
Glioblastoma Recurrent Glioblastoma Brain Tumor Drug: Tesevatinib Phase 2

Expanded Access : Kadmon Corporation, LLC has indicated that access to an investigational treatment associated with this study is available outside the clinical trial.  

Detailed Description:

This is a multicenter, Phase 2 study to assess the activity of tesevatinib in subjects (n = 40) with recurrent glioblastoma. This study will be conducted at up to 10 sites in the United States.

The availability of paraffin-embedded tumor sample diagnostic of glioblastoma is mandatory for entry into the study. Tumor samples will be evaluated for the EGFRvIII mutation and for EGFR gene amplification. Tissue from recurrent surgery is preferred, but tissue from initial surgery is sufficient for study entry. Baseline MRI is mandatory.

After completion of the screening assessments and confirmation of study eligibility by the Medical Monitor upon review of an inclusion package, tesevatinib will be orally administered to all patients at a dose of 300 mg once daily. A cycle will be considered as 28 days. Patients will be evaluated for efficacy according to the Response Assessment in Neuro-Oncology (RANO) criteria.

Patients who develop ≥ Grade 3 adverse event(s) considered by the investigator to be related to study drug will have study treatment interrupted until the drug-related toxicities have resolved to ≤ Grade 1. Once toxicities have resolved to ≤ Grade 1, the patient may resume study treatment at a reduced dose of 250 mg/day. No more than 1 dose reduction is permitted. Patients who require more than one dose reduction will have study drug discontinued and enter the Follow-up Period.

Patients for whom toxicity persists beyond 21 days despite dose interruption may resume study treatment only with permission from the responsible Medical Monitor.

If study treatment is withheld, the patient should be instructed not to make up the withheld doses.

Study treatment will continue until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death. Assessments for disease response will occur at Week 4 and Week 8 and then every 8 weeks thereafter using the RANO criteria.

Upon treatment discontinuation, patients will be followed every 8 weeks for survival.

Tumor samples will be used for exploratory biomarker research including, but not limited to, evaluation of EGFRvIII expression by immunohistochemistry or real-time Polymerase Chain Reaction. An appropriate definition and cutoff for EGFRvIII^pos tumors will be established, and outcome in this subpopulation will be evaluated in addition to the overall study population.

To characterize the safety and tolerability profile of tesevatinib, patients will be monitored throughout the study for adverse events (all grades), serious adverse events, and any adverse events requiring drug interruption or discontinuation. Patients will undergo safety evaluations, including physical examinations, Karnofsky Performance Status (KPS), vital sign measurements, hematology, serum chemistry, urinalysis and electrocardiogram.

Magnetic resonance imaging (MRI) will be used to evaluate the tumor at baseline. All MRIs taken on study patients will be submitted to the sponsor for possible retrospective analysis.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
Actual Study Start Date : June 2016
Actual Primary Completion Date : April 30, 2020
Actual Study Completion Date : April 30, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Glioblastoma
The single arm design assessing progression-free survival at 6 months (PFS-6) in the overall population with the ability to detect a rate of 25% is appropriate as a preliminary test of activity in patients with glioblastoma. The sample size of this study is also designed to permit the comparison of results with EGFR amplified and non-amplified tumors, as well as EGFRvIII mutated versus wild-type. The sample size is adequate to characterize the safety profile in patients with glioblastoma.
Drug: Tesevatinib
Other Name: KD019, XL647




Primary Outcome Measures :
  1. Efficacy: Median Progression-free Survival (PFS) Rate at 6 Months (PFS-6) [ Time Frame: 6 months ]
    Proportion (%) of subjects who did not have progressive disease after treatment with tesevatinib at 6 months (PFS-6) after baseline


Secondary Outcome Measures :
  1. Efficacy: Median PFS [ Time Frame: Until disease progression, unacceptable toxicity, subject or clinician decision to discontinue, death, or up to 3 years, whichever occurred first ]
    Median duration (months) of subjects who were progression-free of disease from baseline

  2. Efficacy: Median Overall Survival Rate at 9 Months (OS-9) [ Time Frame: 9 months ]
    Median proportion (%) of subjects who survived 9 months after baseline

  3. Efficacy: Median OS [ Time Frame: Until unacceptable toxicity, subject or investigator decision to discontinue, death, or up to 3 years, whichever occurred first ]
    Median duration (months) subjects survived from baseline until death

  4. Efficacy: Best Overall Response [ Time Frame: Until disease progression, unacceptable toxicity, subject or investigator decision to discontinue, death, or up to 3 years, whichever occurred first ]
    Best overall response that subjects had to treatment with tesevatinib: complete response (CR), partial response (PR), stable disease (SD), or non-response/progressive disease (PD)

  5. Efficacy: Objective Response Rate (ORR) [ Time Frame: Until disease progression, unacceptable toxicity, subject or investigator decision to discontinue, death, or 3 years, whichever occurred first ]
    Proportion (%) of subjects who had either a complete response (CR) or a partial response (PR) to treatment with tesevatinib

  6. Exposure to Tesevatinib: Overall Mean [ Time Frame: Until disease progression, unacceptable toxicity, subject or investigator decision, death, or up to 3 years, whichever occurred first ]
    Mean total amount of tesevatinib (mg) subjects received during the study

  7. Exposure to Tesevatinib: Overall Median [ Time Frame: Until disease progression, unacceptable toxicity, subject or investigator decision, death, or up to 3 years, whichever occurred first ]
    Median amount of tesevatinib (mg) subjects received during the study

  8. Exposure to Tesevatinib: Mean Number of Cycles [ Time Frame: Until disease progression, unacceptable toxicity, subject or investigator decision, death, or up to 3 years, whichever occurred first. ]
    Mean number of 28-day cycles of treatment with tesevatinib subjects received during the study

  9. Exposure to Tesevatinib: Median Number of Cycles [ Time Frame: Until disease progression, unacceptable toxicity, subject or investigator decision, death, or up to 3 years, whichever occurred first ]
    Median number of 28-day cycles of treatment with tesevatinib subjects received during the study



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Willingness and ability to provide written informed consent and to comply with the study protocol as judged by the investigator
  2. Age ≥ 18 years old
  3. Kamofsky performance status ≥70%
  4. Stable or decreasing dose of corticosteroids within 5 days prior to study 5. enrollment.
  5. For women who are not postmenopausal (i.e., < 12 months after last menstruation) or surgically sterile (absence of ovaries and/or uterus) and who are sexually active: agreement to use an adequate method of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly) during the treatment period and for at least 6 months after the last dose of study drug.
  6. For male patients who are sexually active and who are partners of premenopausal women: agreement to use a barrier method of contraception during the treatment period and for at least 6 months after the last dose of study drug.
  7. Histologically confirmed glioblastoma. A local pathology report constitutes adequate documentation of histology for study inclusion. Patients with an initial diagnosis of a lower-grade glioma are eligible if a subsequent biopsy was determined to be glioblastoma.
  8. First recurrence after concurrent or adjuvant chemoradiotherapy. Imaging confirmation of first tumor progression or regrowth as defined by the RANO criteria . A minimum of 12 weeks must have elapsed from the completion of radiotherapy to study entry to minimize the potential for MRI changes related to radiation necrosis that might be misdiagnosed as progression of disease, unless there is a new lesion outside the radiation field or unequivocal evidence of viable tumor on histopathological sampling.
  9. Prior treatment with TMZ for low grade glioma or glioblastoma.
  10. No more than one prior line of systemic treatment for glioblastoma. Concurrent and adjuvant TMZ-based chemotherapy, including the combination of TMZ with an investigational agent, is considered one line of therapy.
  11. Prior therapy with gamma knife or other focal high-dose radiotherapy is allowed, but the patient must have subsequent histologic documentation of recurrence, unless the recurrence is a new lesion outside the irradiated field.
  12. Recovery from the toxic effects of prior therapy, with a minimum time of:

    1. ≥ 28 days elapsed from the administration of any prior cytotoxic agents, except ≥ 14 days from vincristine, ≥ 21 days from procarbazine, and ≥ 42 days from nitrosureas
    2. ≥ 28 days elapsed from the administration of any investigational agent
    3. ≥ 14 days elapsed from administration of any non-cytotoxic agent (e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid)
  13. Patients who have undergone recent surgery for recurrent or progressive tumor are eligible provided that:

    1. Surgery must have confirmed the recurrence
    2. There must be residual disease
    3. A minimum of 28 days must have elapsed from the day of surgery to first dose of the study drug. For core or needle biopsy, a minimum of 7 days must have elapsed prior to study entry
  14. Availability of formalin-fixed paraffin-embedded tumor tissue diagnostic of glioblastoma.

Exclusion Criteria:

  1. Concurrent therapeutic intervention (including radiation therapy and NovoTTF).
  2. Prior exposure to EGFR inhibitors.
  3. Prior exposure to bevacizumab or other VEGF- or VEGF-receptor-targeted agent within 8 weeks of study start.
  4. Prior treatment with prolifeprospan 20 with carmustine wafer.
  5. Prior intracerebral agent.
  6. Evidence of recent hemorrhage on baseline MRI of the brain. However, patients with clinically asymptomatic presence of hemosiderin, resolving hemorrhagic changes related to surgery, or presence of punctuate hemorrhage in the tumor are eligible.
  7. Need for urgent palliative intervention for primary disease (e.g., rapidly increasing intracranial pressure, impending herniation, uncontrolled seizures).
  8. Hematology:

    ANC < 1.5 x109/L; Plt < 100 x109/L Hgb < 9.0 g/dL within 7 days prior to enrollment. The use of transfusion or other intervention to achieve Hb ≥ 9 g/dL is acceptable.

  9. T.Bili. ≥ 1.5 x ULN (except in patients diagnosed with Gilbert's disease).
  10. AST(SGOT), ALT(SGPT), or alkaline phosphatase (ALP) ≥ 2.5 x ULN.
  11. S. Creat. > 1.5 x ULN.
  12. K+ or Mg+ < LLN.
  13. In the absence of therapeutic intent to anticoagulate the patient: INR > 1.5 or PT > 1.5 xULN or aPTT > 1.5 xULN Therapeutic anticoagulation.
  14. Known contraindication to MRI, such as cardiac pacemaker, shrapnel or ocular foreign body.
  15. Used any prescription medication during the prior 2 weeks that the investigator judges is likely to interfere with the study or to pose an additional risk to the patient in participating, specifically inhibitors or inducers of cytochrome P450 (CYP)3A4 (refer to Appendix 5). A stable regimen (≥ 4 weeks) of antidepressants of the selective serotonin re-uptake inhibitor (SSRI) class is allowed (common SSRIs include escitalopram oxalate, citalopram, fluvoxamine, paroxetine, sertraline, and fluoxetine).
  16. Taking any drugs associated with torsades de pointes or known to moderately or severely prolong the QTc(F) interval
  17. History of torsades de pointes, ventricular tachycardia or fibrillation, pathologic sinus bradycardia (< 50 bpm), heart block (excluding first degree block, being PR interval only), or congenital long QT syndrome. Patients with a history of atrial arrhythmias should be discussed with the Medical Monitor.
  18. Uncontrolled diabetes, as evidenced by fasting serum glucose level >200 mg/dL
  19. New York Heart Association (NYHA) Grade II or greater congestive cardiac failure.
  20. Has marked prolongation of QTc(F) interval at screening or baseline (QTc[F] interval > 470 msec) using the Fridericia method of correction for heart rate.
  21. History of myocardial infarction (within 12 months) or unstable angina (within 6 months) prior to study enrolment.
  22. History of stroke or transient ischemic attacks within 6 months prior to study enrolment.
  23. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to study enrolment.
  24. Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation).
  25. History of intracranial abscess within 6 months prior to study enrolment.
  26. History of another malignancy in the previous 3 years, with a disease-free interval of < 3 years. Patients with prior history of in situ cancer or basal or squamous cell skin cancer are eligible.
  27. Evidence of any active infection requiring hospitalization or IV antibiotics within 2 weeks prior to study enrolment.
  28. Known hypersensitivity to any excipients of tesevatinib.
  29. Inability to swallow or absorb orally-administered medication.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02844439


Locations
Layout table for location information
United States, Arizona
Center for Neurosciences
Tucson, Arizona, United States, 85718
United States, California
City of Hope
Duarte, California, United States, 91010
University of California, San Francisco (UCSF)
San Francisco, California, United States, 94143
United States, Colorado
University of Colorado Cancer Center
Aurora, Colorado, United States, 80045
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States, 48202
United States, New York
Columbia University, Herbert Irving Comprehensive Cancer Center
New York, New York, United States, 10032
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
United States, Texas
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Utah
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
Sponsors and Collaborators
Kadmon Corporation, LLC
  Study Documents (Full-Text)

Documents provided by Kadmon Corporation, LLC:
Study Protocol  [PDF] April 3, 2019
Statistical Analysis Plan  [PDF] June 30, 2020

Layout table for additonal information
Responsible Party: Kadmon Corporation, LLC
ClinicalTrials.gov Identifier: NCT02844439    
Other Study ID Numbers: KD019-208
First Posted: July 26, 2016    Key Record Dates
Results First Posted: September 22, 2021
Last Update Posted: September 22, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
XL647
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action